Triple-negative breast cancer (TNBC) refers to the kind of breast cancer with negative expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2). It is a heterogeneous disease usually with higher histological grade. It is more aggressive than hormone receptor-positive breast cancer, and is prone to visceral metastasis. At present, cytotoxic drugs are often used for TNBC patients as conventional chemotherapy, but they are easy to cause adverse reactions such as bone marrow suppression, neurotoxicity, resulting in intolerance of patients. Platinum drugs in the treatment of metastatic TNBC also have short efficacy duration and high toxicity, with median overall survival only about 9~12 months. In view of the poor efficacy of TNBC chemotherapy, it is urgent in clinic to find new targeted drugs, so as to develop effective treatment regimens according to the tumor molecular subtypes of patients. This paper mainly reviews the research progress of new targeted drugs for TNBC.